# PHARMACY BENEFACT

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS®

# Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has confirmed that the shortage for Rho-Nitro Pumpspray 0.4 mg/dose Sublingual Spray (DIN 02238998) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 10, 2024**. The following grouping was removed from the Critical Supply Product List **May 9, 2024**.

### **NITROGLYCERIN**

### 0.4 MG / DOSE SUBLINGUAL METERED DOSE SPRAY

| 00002238998 | RHO-NITRO PUMPSPRAY    | SDZ | \$ 0.0421 |
|-------------|------------------------|-----|-----------|
| 00002231441 | NITROLINGUAL PUMPSPRAY | SAV | \$ 0.0800 |

Alberta Blue Cross has confirmed that the shortage for Sandoz Sitagliptin-Metformin 50 mg/850 mg Tablet (DIN 02503964) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 17, 2024**. The following grouping was removed from the Critical Supply Product List **May 17, 2024**.

#### SITAGLIPTIN/ METFORMIN HCL

### **50 MG / 850 MG TABLET**

| 00002503964 | SANDOZ SITAGLIPTIN-METFORMIN | SDZ | \$ 0.8893 |
|-------------|------------------------------|-----|-----------|
| 00002333864 | JANUMET                      | MFC | \$ 1.7465 |

Alberta Blue Cross has confirmed that the shortage for Deferoxamine Mesylate 500 mg/vial Injection (DIN 02241600) manufactured by Pfizer Canada ULC has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 26, 2024**. The following grouping was removed from the Critical Supply Product List **May 27, 2024**.

#### **DEFEROXAMINE MESYLATE**

## **500 MG / VIAL INJECTION**

| 00002241600 | DEFEROXAMINE MESYLATE | PFI | \$ 15.1690 |
|-------------|-----------------------|-----|------------|
| 00001981242 | DESFERAL              | NOV | \$ 16.8420 |

continued next page





continued from previous page

# Removal of temporary benefit from the *Alberta Human Services Drug Benefit Supplement (HSDBS)*

Due to the shortage of extensively hydrolyzed infant formulas and specialized infant formulas in Canada, **United States-labelled Nutramigen A+ Concentrate Infant Formula (PIN 00999300)** manufactured by Mead Johnson Nutrition (Canada) Co., **United States-labelled Similac Alimentum Infant Formula (PIN 00999299)** manufactured by Abbott Nutrition and **United States-labelled Gerber Good Start Extensive HA Infant Formula Powder (PIN 00999296)** manufactured by Nestle Canada Inc. was added as temporary benefits for the *Alberta HSDBS*.

Alberta Blue Cross has confirmed that the shortages for Nutramigen A+ With LGG Oral Powder (PIN 00999817), Nutramigen A+ Hypoallergenic Infant Formula Powder (PIN 00999520), and Enfamil Enfacare A+ Infant Formula Powder (PIN 00999564) manufactured by Mead Johnson Nutrition (Canada) Co. Alimentum (PIN 00999449), and Similac Neosure (PIN 00999465) manufactured by Abbott Nutrition have been resolved.

United States-labelled Nutramigen A+ Concentrate Infant Formula (PIN 00999300), United States-labelled Similac Alimentum Infant Formula (PIN 00999299) and United States-labelled Gerber Good Start Extensive HA Infant Formula Powder (PIN 00999296) will no longer be considered temporary benefits for the *Alberta HSDBS* after June 10, 2024.

# Temporary benefit added to the Alberta HSDBS

Due to the unavailability of Nestle Materna Tablet (NPN 80082297), **Centrum Prenatal Tablet (NPN 80045822)** manufactured by Pfizer Consumer Healthcare will be considered as a temporary benefit for the *Alberta HSDBS*. This grouping was added to the Critical Supply Product List **January 30, 2024**.

As of **May 11, 2024**, all claims for **Centrum Prenatal Tablet (NPN 80045822)** will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at **ab.bluecross.ca/provider/type/pharmacy/home.php**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area) 403-294-4041 (Calgary and area) 1-800-361-9632 (toll free) FAX 780-498-8406 (Edmonton and area) FAX 1-877-305-9911 (toll free) Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php





